UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Aurora kinase inhibitors

Critical reviews in oncology/hematology, 2010-02, Vol.73 (2), p.99-110

2010

Volltextzugriff (PDF)

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

European Journal of Cancer, 2009-07, Vol.45 (10), p.1764-1772

2009

Volltextzugriff (PDF)

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

European journal of cancer (1990), 2011-06, Vol.47 (9), p.1328-1335

2011

Volltextzugriff (PDF)

420 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients

European journal of cancer (1990), 2012-11, Vol.48, p.128-128

2012

Volltextzugriff (PDF)

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Nature (London), 2019-10, Vol.574 (7776), p.127-131

2019

Volltextzugriff (PDF)

1256 POSTER Evaluation of Enrollment in Oncology Phase I Clinical Trials

European journal of cancer (1990), 2011, Vol.47, p.S161-S161

2011

Volltextzugriff (PDF)

1085P Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial

Annals of oncology, 2024-09, Vol.35, p.S719-S719

2024

Volltextzugriff (PDF)

1110P Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors

Annals of oncology, 2024-09, Vol.35, p.S735-S735

2024

Volltextzugriff (PDF)

Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: A phase I study

Lung cancer (Amsterdam, Netherlands), 2008-07, Vol.61 (1), p.123-128

2008

Volltextzugriff (PDF)

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

Annals of oncology, 2015-03, Vol.26 (3), p.598-607

2015

Volltextzugriff (PDF)

456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S746-S747

2022

Volltextzugriff (PDF)

First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts

Annals of oncology, 2019-10, Vol.30, p.v169-v170

2019

Volltextzugriff (PDF)

457P - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts

Annals of oncology, 2019-10, Vol.30, p.v169-v170

2019

Volltextzugriff (PDF)

1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

Annals of oncology, 2020-09, Vol.31, p.S706-S707

2020

Volltextzugriff (PDF)

Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2020-10, Vol.138, p.S12-S13

2020

Volltextzugriff (PDF)

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

Annals of oncology, 2021-09, Vol.32, p.S1313-S1313

2021

Volltextzugriff (PDF)

436P Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)

Annals of oncology, 2021-09, Vol.32, p.S552-S553

2021

Volltextzugriff (PDF)

Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v865-v866

2019

Volltextzugriff (PDF)

LBA29 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v865-v866

2019

Volltextzugriff (PDF)

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii741-viii742

2018

Volltextzugriff (PDF)

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Volltextzugriff (PDF)

Drug Rediscovery Protocol: Expanded use of existing anticancer drugs

Annals of oncology, 2019-10, Vol.30, p.v864-v865

2019

Volltextzugriff (PDF)

LBA27 - Drug Rediscovery Protocol: Expanded use of existing anticancer drugs

Annals of oncology, 2019-10, Vol.30, p.v864-v865

2019

Volltextzugriff (PDF)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Volltextzugriff (PDF)

8097 POSTER Advanced nursing guideline for fever management in patients with solid tumours participating in phase I research

European journal of cancer supplements, 2007, Vol.5 (4), p.437-437

2007

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(57)
Bücher
(1)

Sprache

Englisch
(58)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Oncology
(21)
Biological And Medical Sciences
(16)
Female
(16)
Medical Sciences
(16)
Male
(14)
Pharmacology. Drug Treatments
(14)
Aged
(13)
Middle Aged
(13)
Neoplasms - Drug Therapy
(12)
Adult
(10)
Antineoplastic Agents
(10)
Chemotherapy
(10)
Tumors
(10)
Hematology, Oncology And Palliative Medicine
(7)
Animals
(6)
Antineoplastic Agents - Adverse Effects
(6)
Antineoplastic Agents - Pharmacokinetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Aurora kinase inhibitors

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

420 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

1256 POSTER Evaluation of Enrollment in Oncology Phase I Clinical Trials

1085P Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial

1110P Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors

Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: A phase I study

456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors

First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts

457P - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts

1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

436P Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)

Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

LBA29 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Drug Rediscovery Protocol: Expanded use of existing anticancer drugs

LBA27 - Drug Rediscovery Protocol: Expanded use of existing anticancer drugs

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

8097 POSTER Advanced nursing guideline for fever management in patients with solid tumours participating in phase I research

Suchergebnisse filtern